mTOR as a target in breast cancer: the emerging role of everolimus
| Autor: | Govardhanan Nagaiah, Michael Newton, Jame Abraham |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Oncology
medicine.medical_specialty Everolimus biology medicine.drug_class business.industry medicine.disease Breast cancer Mechanism of action Estrogen Internal medicine medicine biology.protein Radiology Nuclear Medicine and imaging In patient medicine.symptom Aromatase skin and connective tissue diseases business PI3K/AKT/mTOR pathway Tamoxifen medicine.drug |
| Zdroj: | Breast Cancer Management. 1:47-56 |
| ISSN: | 1758-1931 1758-1923 |
| DOI: | 10.2217/bmt.12.5 |
| Popis: | SUMMARY The majority of patients with breast cancer are estrogen- and progesterone-receptor positive, and have benefited from the development of anti-estrogen therapies, such as tamoxifen and aromatase inhibitors. Unfortunately, metastatic patients will eventually develop resistance to these agents. Inhibitors of the mTOR, particularly everolimus, show promising activity in this group of patients. mTOR inhibition appears to reverse resistance to anti-estrogen therapy in the estrogen-receptor-/progesterone-receptor-positive subset. Additionally, they may have a similar effect by reversing anti-HER2 resistance in patients who overexpress HER2. This article reviews the mechanism of action of mTOR inhibitors and summarizes the available clinical data of their use in breast cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|